Postpartum Endometritis Clinical Trial
Official title:
Azithromycin With or Without Amoxicillin to Prevent Peripartum Infection and Sepsis in Laboring High-risk Women: 3-Arm RCT
Verified date | March 2022 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥ 18 hours to identical oral regimens of 1 gram of azithromycin, 1 gram of azithromycin+2 grams of amoxicillin or placebo. Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.
Status | Completed |
Enrollment | 756 |
Est. completion date | October 1, 2020 |
Est. primary completion date | May 15, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Women = 37 weeks' viable singleton or twin gestation in labor planning a vaginal delivery with 1. Prolonged membrane rupture (=8 hours) or 2. Prolonged labor (=18 hours). Exclusion Criteria: - Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization: because standard antibiotic therapy for these conditions may confound trial intervention. - Allergy to azithromycin or amoxicillin - Plan for cesarean delivery prior to enrollment - Fetal demise or major congenital anomaly: Major congenital anomalies may confound assessment of neonatal outcomes and every attempt will be made up front to exclude them from randomization. However, some unrecognized fetal anomalies may inevitably be randomized. These will not be excluded post-randomization from the primary (maternal outcome) analysis; they will be taken into consideration in the secondary analyses of neonatal outcomes. |
Country | Name | City | State |
---|---|---|---|
Cameroon | Cameroon Baptist Convention Health Services | Bamenda |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | Merck Sharp & Dohme LLC |
Cameroon,
ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm. 1999 Sep 15;56(18):1839-88. Review. — View Citation
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96. — View Citation
Tita ATN, Boggess K, Saade G. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2017 Jan 12;376(2):182. doi: 10.1056/NEJMc1614626. — View Citation
WHO. WHO recommendations for prevention and treatment of maternal peripartum infections. Sept 2015 http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/peripartum-infections-guidelines/en/
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Experienced Composite Peripartum Infection or Death | Maternal peripartum infection including chorioamnionitis, endometritis, wound infection/abscess, sepsis, and death | Up to 6 weeks after delivery | |
Secondary | Number of Participants Who Experienced Pyelonephritis | Other Infections | Up to hospital discharge | |
Secondary | Number of Participants Who Experienced Breast Infection | Other infections | Up to 6 weeks after delivery | |
Secondary | Number of Participants Who Experienced Other Infection | Includes Hepatitis B, thyroid infection, vaginal infection, viral infection, leg cellulitis, unknown abdominal infection,malaria | up to 6 weeks after delivery | |
Secondary | Number of Participants Who Experienced Fever | Any fever higher than 38C | up to 6 weeks after delivery | |
Secondary | Number of Participants Who Experienced Hypothermia | Any hypothermia less than 36C | up to 6 weeks after delivery | |
Secondary | Number of Participants Who Needed PP Antibiotic | Any postpartum antibiotic | up to 6 weeks after delivery | |
Secondary | Number of Participants Who Experienced Transfusion | Blood transfusion | up to 6 weeks after delivery | |
Secondary | Number of Participants Who Experienced Stillbirth | Any stillbirth | delivery | |
Secondary | Length of Stay | Length of stay in days | up to 6 weeks postpartum | |
Secondary | Number of Participants Who Experienced a Clinic Visit | Clinic visit after discharge | up to 6 weeks after delivery | |
Secondary | Number of Participants Who Experienced a Maternal Readmission | Maternal readmission | up to 6 weeks after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05603624 -
Effect of Sterile Versus Clean Gloves Intrapartum and Postpartum Infections at Term
|
N/A | |
Completed |
NCT01437228 -
Does Preoperative Vaginal Preparation With Povidone-iodine Before Cesarean Delivery Reduce the Risk of Endometritis?
|
Phase 4 | |
Completed |
NCT04385680 -
Chlorhexidine Vaginal Preparation for Reduction of Post-cesarean Endometritis and Sepsis
|
Phase 1/Phase 2 | |
Terminated |
NCT03478163 -
Antibiotics During Intrauterine Balloon Tamponade Placement
|
Phase 4 | |
Not yet recruiting |
NCT03840889 -
Secondary Postpartum Hemorrhage
|
||
Completed |
NCT05118984 -
Efficacy of Azithromycin in MSAF Cases to Improve Maternal and Neonatal Outcomes
|
Phase 4 |